Cumberland Projects Cash Will Fund Operations for More Than Five Years

Cumberland Pharmaceuticals Inc. expects its remaining cash to fund operations for more than five years, a projection Chief Financial Officer John Hamm outlined as the company prepares a new drug application for ifetroban.

Hamm is Cumberland’s senior vice president of accounting and finance and chief financial officer. The company had $80.6 million in cash as of Sept. 30, 2026. The more-than-five-year runway is a management projection.

Cumberland is preparing a new drug application for ifetroban to treat cardiomyopathy associated with Duchenne muscular dystrophy (DMD). The Food and Drug Administration granted a request for rolling review, which allows completed sections of an application to be submitted before the full application is ready. Cumberland has announced plans to submit the application, which remains in preparation.

The projection came as Cumberland reported third-quarter financial results, including revenue of $2.16 million for the quarter ended Sept. 30, 2026.